This work has been retracted.
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Year: 2010
Type: article
Abstract: Antibody-dependent cell-mediated cytotoxicity (ADCC), which is largely mediated by natural killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 monoclonal antibody (mAb) used to treat patients with B-cell lymphomas. CD137 is a costimulatory molecule expressed on a variety of immune cells after activation, including NK cells. In the present study, we show that an anti-CD137 agonistic mAb enhances the antilymphoma activity of rituximab by enhancing ADCC. Human NK cells up-regulate CD137 after encountering rituximab-coated tumor B cells, and subsequent stimulation of these NK cells with anti-CD137 mAb enhances rituximab-dependent cytotoxicity against the lymphoma cells. In a syngeneic murine lymphoma model and in a xenotransplanted human lymphoma model, sequential administration of anti-CD20 mAb followed by anti-CD137 mAb had potent antilymphoma activity in vivo. These results support a novel, sequential antibody approach against B-cell malignancies by targeting first the tumor and then the host immune system.
Source: Blood
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Awards: G1743793465, Anti-Idiotype Therapy of Human B Cell Malignancy, Clinical and Laboratory Studies of Malignant Lymphomas, Southeast Regional Centers of Excellence for Biodefense & Emerging Infectious Di, Mechanisms of B Cell Responses in Autoimmune Disease, Enhancing tumor-targeted antibody therapy with a second NK activating antibody.
OpenAlex ID: W2113170011